NYSE:EWMedical Equipment
Share Buyback Surge and Upbeat Outlook Might Change the Case for Investing in Edwards Lifesciences (EW)
Earlier this week, Edwards Lifesciences reported strong Q2 results, raised its 2025 guidance, and announced a US$500 million accelerated share repurchase agreement, building on over US$800 million in shares repurchased during 2025.
Despite a legal setback affecting margins, the company sharpened its focus on heart valve therapies after divesting its critical care business, while highlighting robust financial health and ongoing innovation.
With the company’s new share repurchase program...